Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Post Partum Hemorrhage, Fibrinolysis; Hemorrhage, Blood Loss

In brief

The investigators prepared a novel study of tranexamic acid (TXA) designed to estimate the quantity of blood loss in women undergoing elective repeat cesarean deliveries. This is the first trial to utilize a prophylactic dose of TXA prior to incision followed by a subsequent prophylactic dose at placental delivery in obstetric patients undergoing scheduled cesareans. The purpose of this study is to quantify blood loss during uncomplicated repeat cesarean deliveries with and without TXA. The central hypothesis is that TXA administration reduces blood loss and fibrinolysis in women undergoing repeat cesarean sections.

Key facts

Study ID
NCT03856164
Run by
University of Texas Southwestern Medical Center
People needed
110
Starts
2019-06-17
Expected to finish
2020-08-31
Last updated by the study team
2021-01-19

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.